Orient Europharma Co (ROCO:4120) Cyclically Adjusted Revenue per Share: NT$70.16 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4120 Orient Europharma Co Ltd ROCO:4120
61 GF Score
Price NT$45.70
GF Value NT$47.36
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Orient Europharma Co Cyclically Adjusted Revenue per Share?

Orient Europharma Co ROCO:4120 -3.38% 61 Cyclically Adjusted Revenue per Share is NT$70.16 as of Jun. 2026. GuruFocus rates ROCO:4120 with a GF Score™ of 61/100 and a GF Value™ of NT$47.36 (Fairly Valued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Orient Europharma Co's adjusted revenue per share for the three months ended in Jun. 2026 was NT$13.708. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is NT$70.16 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Orient Europharma Co's average Cyclically Adjusted Revenue Growth Rate was -0.20% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -0.20% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 2.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Orient Europharma Co was 4.70% per year. The lowest was -0.20% per year. And the median was 2.85% per year.

As of today (2026-09-04), Orient Europharma Co's current stock price is NT$45.70. Orient Europharma Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was NT$70.16. Orient Europharma Co's Cyclically Adjusted PS Ratio of today is 0.65.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Orient Europharma Co was 1.00. The lowest was 0.47. And the median was 0.65.


Orient Europharma Co  (ROCO:4120) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Orient Europharma Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=45.70/70.16
=0.65

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Orient Europharma Co was 1.00. The lowest was 0.47. And the median was 0.65.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Orient Europharma Co Cyclically Adjusted Revenue per Share Related Terms


Orient Europharma Co Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Orient Europharma Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orient Europharma Co Cyclically Adjusted Revenue per Share Chart

Orient Europharma Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 66.71 69.86 70.45 69.92 69.44

Orient Europharma Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 70.28 70.08 69.44 70.03 70.16

ROCO:4120 vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Orient Europharma Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Orient Europharma Co Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Orient Europharma Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Orient Europharma Co's Cyclically Adjusted PS Ratio falls into.


ROCO:4120
61GF Score
Orient Europharma Co Ltd ROCO:4120
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Orient Europharma Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Orient Europharma Co's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=13.708/333.9520*333.9520
=13.708

Current CPI (Jun. 2026) = 333.9520.

Orient Europharma Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 14.782 241.428 20.447
201612 15.672 241.432 21.678
201703 15.292 243.801 20.947
201706 14.181 244.955 19.333
201709 15.402 246.819 20.839
201712 15.186 246.524 20.572
201803 15.691 249.554 20.998
201806 15.060 251.989 19.958
201809 15.813 252.439 20.919
201812 16.453 251.233 21.870
201903 17.268 254.202 22.685
201906 17.610 256.143 22.959
201909 16.977 256.759 22.081
201912 18.354 256.974 23.852
202003 17.804 258.115 23.035
202006 15.513 257.797 20.096
202009 13.093 260.280 16.799
202012 15.121 260.474 19.387
202103 13.966 264.877 17.608
202106 13.664 271.696 16.795
202109 13.068 274.310 15.909
202112 14.624 278.802 17.517
202203 13.154 287.504 15.279
202206 13.848 296.311 15.607
202209 12.677 296.808 14.263
202212 14.802 296.797 16.655
202303 13.265 301.836 14.676
202306 13.065 305.109 14.300
202309 12.597 307.789 13.668
202312 13.859 306.746 15.088
202403 12.730 312.332 13.611
202406 12.469 314.175 13.254
202409 12.195 315.301 12.916
202412 13.070 315.605 13.830
202503 13.313 319.799 13.902
202506 13.056 322.561 13.517
202509 12.898 324.800 13.261
202512 13.804 324.054 14.226
202603 13.361 330.213 13.512
202606 13.708 333.952 13.708

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of NT$70.16 mean?
Orient Europharma Co (ROCO:4120) has a Cyclically Adjusted Revenue per Share of NT$70.16 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Orient Europharma Co and its competitors.
Is Orient Europharma Co's Cyclically Adjusted Revenue per Share too high?
Orient Europharma Co's current Cyclically Adjusted Revenue per Share is NT$70.16. Overall, Orient Europharma Co has a GF Score™ of 61/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Orient Europharma Co's Cyclically Adjusted Revenue per Share compare to ZTS?
Orient Europharma Co's Cyclically Adjusted Revenue per Share of NT$70.16 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Orient Europharma Co and its competitors. Orient Europharma Co's current Cyclically Adjusted Revenue per Share is NT$70.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orient Europharma Co stock overvalued right now?
Based on GuruFocus' analysis, Orient Europharma Co (ROCO:4120) is currently considered Fairly Valued. The stock's GF Value™ is NT$47.36, compared to a current price of NT$45.70 — trading 3.5% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is NT$70.16. Orient Europharma Co's overall GF Score™ is 61/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Orient Europharma Co (ROCO:4120), the current Cyclically Adjusted Revenue per Share is NT$70.16 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Orient Europharma Co (ROCO:4120) Overvalued in 2026?

Based on GuruFocus' analysis, Orient Europharma Co stock appears to be undervalued. The current stock price of NT$45.70 is trading 3.5% below its estimated GF Value™ of NT$47.36. GuruFocus considers Orient Europharma Co to be Fairly Valued.

Key valuation signals for ROCO:4120:

  • Cyclically Adjusted Revenue per Share: NT$70.16
  • GF Value™: NT$47.36 vs. price of NT$45.70 (3.5% below fair value)
  • GF Score™: 61/100 with 5 warning signs

No single metric tells the full story. See the ROCO:4120 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Orient Europharma Co Business Description

Address 13th Floor, No. 128, Chengde Road, Section 6, Beitou District, Taipei, TWN, 112052
Orient Europharma Co Ltd is a Taiwan-based company engaged in the wholesale of Western Pharmaceutical and Medical Devices. The firm also manufactures drugs and medicines, Beverages, Cleaning Preparations, Cosmetics, Medical Devices, and Other Food Products. Its products cover various therapeutic areas, including the central nervous system, cardiovascular, diabetes, allergy, cosmetics, and health supplements. The company's segments include: Western Pharma BU which includes manufacture and sale of pharmaceutical and cosmetic products; and Nutricare BU includes sale of various nutrition supplements and consumable healthcare products. It derives maximum revenue from Western Pharma BU segment. Geographically, it operates in Taiwan, China, and Southeast Asia.
61GF Score

Get the complete analysis for ROCO:4120

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$45.70
Price
NT$47.36
GF Value